Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase b Study

被引：0
|
作者：
Lu, Qianjin [1 ]
Yang, Bin [2 ]
Liu, Lunfei [3 ]
Li, Linfeng [4 ]
Liu, Weijun [5 ]
Yao, Xu [1 ]
Man, Xiaoyong [6 ]
Chen, Aijun [7 ]
Shi, Yuling [8 ]
Ding, Yangfeng [8 ]
Sun, Qing [9 ]
Tao, Juan [10 ]
Liang, Chris [11 ]
Liu, Yong [11 ]
Liu, Donghua [11 ]
Sun, Peiyu [11 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Dermatol, Beijing, Peoples R China
[2] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 4, Hangzhou, Peoples R China
[4] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China
[5] Dermatol Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[7] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai Skin Dis Hosp, Shanghai, Peoples R China
[9] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[10] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[11] Hangzhou Highlightll Pharmaceut Co Ltd, Hangzhou, Peoples R China
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L36
引用
收藏
页码：AB372 / AB372
页数：1
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF MIRIKIZUMAB THERAPY IN PEDIATRIC PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Kaplan, Jess
    Bousvaros, Athos
    Turner, Dan
    Dubinsky, Marla C.
    Komocsar, Wendy
    Larkin, Amy E.
    Johns, Jordan
    Zhang, Xin
    Crandall, Wallace
    Arora, Vipin
    Todd, Kris
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2024, 166 (05) : S819 - S820
  • [42] H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects - A Retrospective Survey Study
    Weller, Karsten
    Ziege, Claudia
    Staubach, Petra
    Brockow, Knut
    Siebenhaar, Frank
    Krause, Karoline
    Altrichter, Sabine
    Church, Martin K.
    Maurer, Marcus
    PLOS ONE, 2011, 6 (09):
  • [43] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
    Gratacos, Jordi
    Turkiewicz, Anthony
    Dokoupilova, Eva
    Gellett, Amanda
    Sprabery, Aubrey
    Geneus, Vladimir
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [44] Interferon-b-1a in Active Moderate to Severe Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter Study
    Mannon, Peter
    Panaccione, Remo
    Miner, Philip
    McAllister, Arthur
    O'Gorman, John
    Cataldi, Fabio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S446 - S446
  • [45] Chronic spontaneous/idiopathic urticaria patients with moderate activity have similar burden of disease as those with severe activity - results from the ASSURE-CSU study
    Marsland, A.
    Abuzakouk, M.
    Balp, M. M.
    Berard, F.
    Canonica, G. W.
    Gimenez-Arnau, A.
    Grattan, C.
    Hollis, K.
    Hunter, S.
    Khalil, S.
    Knulst, A. C.
    Lacour, J. P.
    Lynde, C.
    McBride, D.
    Nakonechna, A.
    Ortiz, De Frutoz F. J.
    Oude, Elberink J. N.
    Sussman, G.
    Tian, H.
    Weller, K.
    Maurer, M.
    ALLERGY, 2017, 72 : 95 - 95
  • [46] Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results
    Hsu, Connie
    Snyder, Robert
    Clore, Lee
    Jain, Vipul
    Gimenez-Arnau, Ana
    Lheritier, Karine
    Walsh, Pauline
    Haemmerle, Sibylle
    Wells, Michael
    Nikolaev, Ivan
    Maurer, Marcus
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
  • [47] REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS
    Clore, L.
    Jain, V.
    Gimenez-Arnau, A.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S32 - S32
  • [48] REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Gimenez-Arnau, A.
    Hayama, K.
    Jain, V.
    Lheritier, K.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S11 - S11
  • [49] Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study
    Hide, Michihiro
    Igarashi, Atsuyuki
    Yagami, Akiko
    Chinuki, Yuko
    Inomata, Naoko
    Fukunaga, Atsushi
    Kaiser, Guenther
    Wang, Junyi
    Matsushima, Soichiro
    Greenberg, Steven
    Khalil, Sam
    ALLERGOLOGY INTERNATIONAL, 2018, 67 (02) : 243 - 252
  • [50] LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Soong, W.
    Lanier, B.
    Kobayashi, K.
    Barve, A.
    Hua, E.
    Janocha, R.
    Severin, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S28
12345